European consensus for the diagnosis of MCI _QUADAS-II assessment

Using a modified Delphi procedure, a European task force is defining a diagnostic workflow for etiologicical and biomarker-based diagnosis of neurocognitive disorders, in which expert expertise fills evidence gaps for validity and prioritization of biomarkers. The panel of experts is asked to answer a Delphi questionnaire and justify their answers with evidence from the literature. We then provided the experts with data on the diagnostic accuracy of biomarkers (MRI, amyloid PET, tau and FDG, MIBG scintigraphy, DaT-SPECT, EEG and polysomnography) in predicting clinical progression from prodromal stages to mild dementia in neurocognitive disorders. Keywords used for literature search in Medline database are in the .pdf file.
We assessed the quality of evidence from the included literature using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). The data were recorded in the attached Excel sheet.

运用改良的德尔菲程序，一支欧洲工作组正在确立基于病因学和生物标志物诊断神经认知障碍的诊断工作流程。在此流程中，专家们的专业见解填补了证据空白，以确保生物标志物的有效性和优先级。专家小组被要求回答德尔菲问卷，并利用文献中的证据来论证其答案。随后，我们向专家们提供了关于生物标志物（MRI、淀粉样蛋白PET、tau和FDG、MIBG闪烁扫描、DaT-SPECT、EEG和多导睡眠图）在预测神经认知障碍从前驱期到轻度痴呆的病程进展中的诊断准确性的数据。用于Medline数据库文献检索的关键词已收录于附带的.pdf文件中。我们运用诊断准确性研究质量评估（QUADAS-2）对纳入文献的证据质量进行了评估。数据记录于所附的Excel表中。